Serum Levels of IL-17 and IL-23 in Patients With Rheumatic Mitral Stenosis

Basit Öğe Kaydı
dc.contributor.authorBilik, Mehmet Zihni
dc.contributor.authorKaplan, Ibrahim
dc.contributor.authorPolat, Nihat
dc.contributor.authorAkil, Mehmet Ata
dc.contributor.authorAkyuz, Abdurrahman
dc.contributor.authorAcet, Halit
dc.contributor.authorYuksel, Murat
dc.date.accessioned2024-04-24T17:08:20Z
dc.date.available2024-04-24T17:08:20Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractRheumatic mitral valve stenosis (RMS) is a complication of rheumatic heart disease (RHD) and leads to significant morbidity and mortality. RHD is a chronic inflammatory and autoimmune disease that is associated with cytokine activities. The etiology of RMS is not fully understood yet. Interleukin (IL)-17 and IL-23 have a key role in development of the autoimmunity. The expression of these cytokines in RMS remains unclear. In this study, we investigated the serum levels of IL-17 and IL-23 in RMS patients compared to healthy subjects. A total of 35 patients admitted to cardiology outpatient clinic between December 2014 and May 2015 who were diagnosed with RMS formed the study group. Age- and gender-matched 35 healthy subjects were included as the control group. Statistical analyses were performed using SPSS 18.0 and P value <0.05 was considered as statistically significant. The patients with RMS had higher WBC count, hsCRP, systolic pulmonary artery pressure (PAPs), left atrial diameter (LAD), IL-17, and IL-23 levels compared to the control subjects. The levels of IL-17 (P = 0.012) and IL-23 (P = 0.004) were significantly higher in the RMS group. Correlation analysis revealed that IL-17 and IL-23 levels had a significant correlation with each other and with hsCRP and LAD. We demonstrated that serum levels of IL-17 and IL-23 are significantly higher in patients with RMS compared to those of healthy subjects. IL-17 and IL-23 expression may have a possible role in inflammatory processes that result in RMS development.en_US
dc.identifier.doi10.1097/MD.0000000000003562
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue18en_US
dc.identifier.pmid27149476
dc.identifier.scopus2-s2.0-84969749450
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000003562
dc.identifier.urihttps://hdl.handle.net/11468/17305
dc.identifier.volume95en_US
dc.identifier.wosWOS:000376926000041
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofMedicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keyword]en_US
dc.titleSerum Levels of IL-17 and IL-23 in Patients With Rheumatic Mitral Stenosisen_US
dc.titleSerum Levels of IL-17 and IL-23 in Patients With Rheumatic Mitral Stenosis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu